Loading...
•
Mar 31, 2024
•/
DBV Technologies Q1 2024 Earnings Report
DBV Technologies reported financial results and business update for Q1 2024.
Key Takeaways
DBV Technologies reported a net loss of $27.3 million for Q1 2024, with cash and cash equivalents at $101.5 million. The company is progressing with its VITESSE Phase 3 clinical trial and appointed a new Chief Regulatory Officer.
VITESSE enrollment is on track to screen the last patient by Q3 2024.
Robert Pietrusko was appointed as Chief Regulatory Officer.
Q1 2024 closed with a cash balance of $101.5 million.
Net loss for the quarter was $27.3 million.
Forward Guidance
DBV Technologies expects its cash and cash equivalents to fund operations until December 31, 2024, and intends to seek additional capital for research and development efforts and potential launch of Viaskin Peanut.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...